Alliance Pharma’s buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the size of the company and providing a more internationally-oriented business. The enlarged group is also a more attractive and credible partner for attracting in–licensing and M&A opportunities. 2017 looks set to be an exciting year for the group. Not only is there solid growth potential in the re-focused group, but approval of Diclectin in the UK also offers significant growth potential.
25 Jan 2017
Potential of Diclectin
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Potential of Diclectin
Alliance Pharma plc (APH:LON) | 36.6 -0.1 (-0.8%) | Mkt Cap: 197.7m
- Published:
25 Jan 2017 -
Author:
Martin Hall -
Pages:
28
Alliance Pharma’s buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the size of the company and providing a more internationally-oriented business. The enlarged group is also a more attractive and credible partner for attracting in–licensing and M&A opportunities. 2017 looks set to be an exciting year for the group. Not only is there solid growth potential in the re-focused group, but approval of Diclectin in the UK also offers significant growth potential.